Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: High Risk Cervical Cancer Clear all
Completed Phase 1 Interventional Results available

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

NCT03894618
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions
SL-279252
Drug
Lead sponsor
Shattuck Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 17, 2026, 3:06 AM EDT
Terminated Phase 2 Interventional Results available

A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

NCT03840967
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer, Adenocarcinoma
Interventions
Niraparib
Drug
Lead sponsor
Shadia Jalal, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Tampa, Florida • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 17, 2026, 3:06 AM EDT
Not listed Phase 1Phase 2 Interventional

Radiation Therapy Following Surgery in Treating Patients With Recurrent or Second Primary Cancer of the Head and Neck Following Previous Radiation Therapy

NCT00004226
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Birmingham, Alabama • Loma Linda, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 1Phase 2 Interventional

Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer

NCT00004048
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
filgrastim, doxorubicin hydrochloride, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Biological · Drug · Procedure + 1 more
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
16 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Belleville, New Jersey • Paterson, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Sep 17, 2026, 3:06 AM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00117884
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 17, 2026, 3:06 AM EDT
Recruiting Phase 1 Interventional

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Clear Cell Adenocarcinoma, Chondrosarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Ovarian High Grade Serous Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Melanoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
Interventions
Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Terminated Phase 1 Interventional Results available

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

NCT03991741
View directory record Official record
Conditions
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
Interventions
Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
Biological
Lead sponsor
Gregory Daniels
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 17, 2026, 3:06 AM EDT
Active, not recruiting Phase 2 Interventional

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

NCT03228667
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions
N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
35
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

NCT04712851
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
Interventions
Pembrolizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Suspended Phase 2 Interventional

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

NCT05337735
View directory record Official record
Conditions
Microsatellite High Cancers, Peritoneal Mesothelioma, Extrapulmonary High Grade, Neuroendocrine Carcinomas, Cervical Carcinoma, Hodgkin's Lymphoma, Pleural Mesothelioma, Small Cell Lung Cancer
Interventions
XmAb20717
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

NCT06234748
View directory record Official record
Conditions
Oropharynx Cancer, HPV-Related Carcinoma
Interventions
Radiation, Platinum based chemotherapy
Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 4 Interventional Results available

Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.

NCT00754468
View directory record Official record
Conditions
Barrett's Esophagus, Esophageal Cancer
Interventions
Cryo Spray Ablation
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 17, 2026, 3:06 AM EDT
Active, not recruiting Phase 1 Interventional

Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer

NCT02285192
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer
Interventions
18F-Fluorodeoxyglucose (18F-FDG), PET/CT imaging, PET/MRI imaging
Radiation · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reshaping Postpartum Follow-up

NCT06054841
View directory record Official record
Conditions
Hypertension in Pregnancy, Gestational Diabetes, Cervical Dysplasia
Interventions
Postpartum follow up card, Control
Behavioral · Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 17, 2026, 3:06 AM EDT
Recruiting Not applicable Interventional

High-Resolution PET-CT Imaging for Surgical Margin Visualization

NCT06915454
View directory record Official record
Conditions
Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Interventions
Intra-op PET/CT Specimen Scanner
Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Terminated Phase 1 Interventional

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

NCT06034860
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer
Interventions
MT-8421, Nivolumab
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease

NCT00709891
View directory record Official record
Conditions
Human Papilloma Virus (HPV)
Interventions
cobas® 4800 HPV Test
Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
21 Years and older · Female only
Enrollment
47,208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
61
States / cities
Enterprise, Alabama • Hoover, Alabama • Mobile, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2015 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

NCT01156142
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
Interventions
doxepin hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
120
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 17, 2026, 3:06 AM EDT
Recruiting Phase 3 Interventional

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

NCT06992427
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions
Gabapentin, Placebo, Chemotheraphy, Radiation Therapy, Analgesic Agent, Biospecimen Collection, Survey Administration
Drug · Radiation · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
200
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Results available

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

NCT02354534
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
Interventions
Artesunate Suppositories
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 17, 2026, 3:06 AM EDT
Terminated Phase 1 Interventional

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

NCT02952989
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Colorectal Neoplasms, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
SGN-2FF, pembrolizumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Not applicable Interventional

Focal Ablation of Cervical Precancer

NCT01709773
View directory record Official record
Conditions
High-grade Cervical Intraepithelial Neoplasia
Interventions
Focal treatment
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 1 Interventional

Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer

NCT00078494
View directory record Official record
Conditions
Nasopharyngeal Neoplasms
Interventions
EBV-LMP-2
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 1 Interventional

Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

NCT02829931
View directory record Official record
Conditions
Malignant Glioma
Interventions
Hypofractionated Stereotactic Irradiation, Nivolumab, Bevacizumab, Ipilimumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 17, 2026, 3:06 AM EDT